Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process
Suven Pharmaceuticals Ltd Q1FY25; 50% fall in Profits
Categories
CDMO
Suven Pharmaceuticals Ltd Q4FY24; 57% fall in Profits
Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process
Suven Pharmaceuticals Ltd Q2FY24; 11% rise in Profits
Suven Pharma is in the business of Contract development & manufacturing organisation (CDMO), catering to the needs of global Pharma Industry. Financial
Venus Remedies Ltd Q1FY24; 83% fall in Profits
Venus Remedies Ltd is an Indian Pharmaceutical company with a presence in domestic and international markets. It is primarily engaged in the
Sakar Healthcare Ltd Q1FY24; 1% fall in Profits
Sakar Healthcare Ltd is engaged in manufacturing of Pharmaceutical formulations in the form of liquid injectables, tablets/ capsules, oral liquid syrups, dry
Sanofi India Ltd Q1FY24; 2% rise in Profits
Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products. Financial Results: Sanofi India Ltd reported Revenues for Q1FY24
Suven Pharmaceuticals Ltd Q1FY24; 12% rise in Profits
Suven Pharma is in the business of Contract development & manufacturing organisation (CDMO), catering to the needs of global Pharma Industry. Financial
Windlas Biotech Ltd Q1FY24; 20% rise in Profits
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid
Sun Pharmaceuticals Ltd Q4FY23 results out, revenue grows by 16%
Sun Pharmaceuticals Ltd reported Total revenue for Q4 FY23 of ₹10,931 Crore, up from ₹9,447 Crore year on year depicting a growth
Suven Pharmaceuticals Ltd Q4FY23 results out, net profit grows by 35%
Suven Pharma is in the business of Contract development & manufacturing organisation (CDMO), catering to the needs of global Pharma Industry. SPL
Suven pharmaceuticals Q3FY23 net profit drops by 33 percent
The company has reported total income of INR 366.78 crores during the period ended December 31, 2022 as compared to INR 456.27
Jubilant Pharmova reports dip in its net profit by 97% for Q2FY23
Jubilant Pharmova reported total income of INR 1,599.5 crores during the period ended September 30, 2022 as compared to INR 1,657.7 crores
Jubilant Pharmova reports dip in its net profit by 71% for Q1FY23
Jubilant Pharmova reported total income of INR 1,452 crores during the period ended June 30, 2022 as compared to INR 1,635 crores